

Tiago A Mestre

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5733218/tiago-a-mestre-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

1,494
citations

23
h-index

35
g-index

110
ext. papers

2,019
ext. citations

5.2
avg. IF

4.97
L-index

#	Paper	IF	Citations
94	A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. <i>Movement Disorders</i> , 2019 , 34, 657-663	7	115
93	Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 212-224	2.2	93
92	Therapeutic interventions for symptomatic treatment in Huntington's disease. <i>The Cochrane Library</i> , 2009 , CD006456	5.2	67
91	Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1192-202	7	66
90	Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. <i>Movement Disorders</i> , 2014 , 29, 1751-6	7	56
89	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016 , 31, 290-6	7	54
88	Canadian guideline for Parkinson disease. <i>Cmaj</i> , 2019 , 191, E989-E1004	3.5	44
87	Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1570-1574	7	44
86	MDS evidence-based review of treatments for essential tremor. <i>Movement Disorders</i> , 2019 , 34, 950-958	7	43
85	Transducer-based evaluation of tremor. <i>Movement Disorders</i> , 2016 , 31, 1327-36	7	43
84	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 102-106	3.6	42
83	5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 411-21	5.9	41
82	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. <i>Journal of Huntingtons Disease</i> , 2017 , 6, 157-163	1.9	39
81	Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2018 , 15, 97	5.3	36
80	Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis. <i>Neurology</i> , 2017 , 88, 2216-2224	6.5	35
79	Therapeutic interventions for disease progression in Huntington's disease. <i>The Cochrane Library</i> , 2009 , CD006455	5.2	33
78	Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. <i>Neurology</i> , 2014 , 82, 1402-9	6.5	32

77	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016 , 31, 1466-1478	7	31
76	Restless genital syndrome in Parkinson disease. <i>JAMA Neurology</i> , 2014 , 71, 1559-61	17.2	30
75	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 167-72	5.5	29
74	Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. <i>PLoS ONE</i> , 2016 , 11, e0157852	3.7	29
73	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019 , 34, 676-681	7	28
72	Diagnosis and treatment of impulse control disorders in patients with movement disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2013 , 6, 175-88	6.6	26
71	What motivates Parkinson's disease patients to enter clinical trials?. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 667-71	3.6	22
70	Development of the Integrated Parkinson's Care Network (IPCN): using co-design to plan collaborative care for people with Parkinson's disease. <i>Quality of Life Research</i> , 2019 , 28, 1355-1364	3.7	22
69	Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies. <i>Neurotherapeutics</i> , 2020 , 17, 1645-1659	6.4	18
68	Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics. <i>Current Neurology and Neuroscience Reports</i> , 2017 , 17, 18	6.6	17
67	Rating scales for cognition in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018 , 33, 187-195	7	17
66	A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. <i>Neurogenetics</i> , 2016 , 17, 245-249	3	17
65	Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 111-117	2.2	17
64	What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1349-54	3.6	16
63	Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?. <i>Movement Disorders</i> , 2018 , 33, 1228-1235	7	16
62	Nocebo response in Parkinson's disease: A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 13-19	3.6	14
61	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 915-8	3.6	14
60	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 67-69	2.2	13

59	Therapy of Parkinson's Disease Subtypes. <i>Neurotherapeutics</i> , 2020 , 17, 1366-1377	6.4	13
58	Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 361-372	2.2	12
57	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. <i>Movement Disorders</i> , 2018 , 33, 742-749	7.49	12
56	Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features. <i>Parkinsonism and Related Disorders</i> , 2018 , 53, 42-45	3.6	12
55	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2018 , 8, 503-510	5.3	12
54	Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: theIP EDIGT score. <i>European Journal of Neuroscience</i> , 2017 , 45, 175-191	3.5	11
53	Technology-Enabled Care: Integrating Multidisciplinary Care in Parkinson's Disease Through Digital Technology. <i>Frontiers in Neurology</i> , 2020 , 11, 575975	4.1	11
52	Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. <i>Frontiers in Neurology</i> , 2016 , 7, 27	4.1	11
51	Recent advances in the therapeutic development for Huntington disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 59, 125-130	3.6	11
50	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018 , 33, 960-965	7	10
49	Moving towards home-based community-centred integrated care in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 21-26	3.6	9
48	Are genetic and idiopathic forms of Parkinson's disease the same disease?. <i>Journal of Neurochemistry</i> , 2020 , 152, 515-522	6	8
47	Measurement Instruments to Assess Functional Mobility in Parkinson's Disease: A Systematic Review. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 129-139	2.2	8
46	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinsons Disease</i> , 2018 , 8, 131-139	5.3	7
45	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 395-404	5.3	7
44	Current use of domperidone and co-prescribing of medications that increase its arrhythmogenic potential among older adults: a population-based cohort study in Ontario, Canada. <i>Drugs and Aging</i> , 2014 , 31, 805-13	4.7	6
43	Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic. <i>Parkinsonism and Related Disorders</i> , 2021 , 86, 97-100	3.6	6
42	Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. <i>Lancet Neurology</i> , 2018 , 17, 842	24.1	6

41	Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology, The</i> , 2017 , 16, 28-29	24.1	5
40	Reluctance to start medication for Parkinson's disease: a mutual misunderstanding by patients and physicians. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 608-12	3.6	5
39	Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 398-406	7	5
38	A MDS Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2021 ,	7	4
37	Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial. <i>Movement Disorders</i> , 2020 , 35, 2319-2323	7	4
36	The Integrated Parkinson's disease Care Network (IPCN): Qualitative evaluation of a new approach to care for Parkinson's disease. <i>Patient Education and Counseling</i> , 2021 , 104, 136-142	3.1	4
35	Impact of New Technologies in a Stroke Presentation: A Case of Dystextia and Dystypia. <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 458-460	1	3
34	Are placebo pills presented as experimental treatment a true placebo?. <i>Pain</i> , 2017 , 158, 535	8	3
33	Synuclein Meeting 2019: where we are and where we need to go. <i>Journal of Neurochemistry</i> , 2019 , 150, 462-466	6	3
32	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , 2018 , 33, 1195-1203	7	3
31	The dawn of a new era for neurodegenerative disorders: Huntington's disease leading the way. <i>Movement Disorders</i> , 2019 , 34, 1301-1302	7	3
30	The Role of Architecture and Design in the Management of Parkinson's Disease: A Systematic Review. <i>Journal of Parkinsons Disease</i> , 2020 , 10, 1301-1314	5.3	3
29	Moving towards Integrated and Personalized Care in Parkinson's Disease: A Framework Proposal for Training Parkinson Nurses. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	3
28	Nocebo and lessebo effects. <i>International Review of Neurobiology</i> , 2020 , 153, 121-146	4.4	2
27	Toward e-Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 208-214	2.2	2
26	The placebo response in Parkinson's disease and other movement disorders. <i>Movement Disorders</i> , 2018 , 33, 1193-1194	7	2
25	Therapeutic interventions for symptomatic treatment in Huntington's disease 2007 ,		1
24	Remote Evaluation of Parkinson's Disease Using a Conventional Webcam and Artificial Intelligence.. <i>Frontiers in Neurology</i> , 2021 , 12, 742654	4.1	1

23	Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 1-10	1	1
22	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021 , 36, 1964-1967	7	1
21	Huntington's Disease Integrated Staging System (HD-ISS): A Novel Evidence-Based Classification System For Staging		1
20	Drooling rating scales in Parkinson's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2021 , 91, 173-180	3.6	1
19	Co-designing a digital companion with people living with Parkinson's to support self-care in a personalized way: The eCARE-PD Study.. <i>Digital Health</i> , 2022 , 8, 20552076221081695	4	1
18	Disease Burden of Huntington's Disease (HD) on People Living with HD and Care Partners in Canada.. <i>Journal of Huntingtons Disease</i> , 2022 ,	1.9	1
17	A rare cause of orofacial dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2018 , 50, 122-123	3.6	0
16	Epidemiology and economic burden of Huntington's Disease: a Canadian provincial public health system perspective.. <i>Journal of Medical Economics</i> , 2022 , 1-21	2.4	0
15	Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme. <i>Parkinsonism and Related Disorders</i> , 2021 , 93, 89-96	3.6	0
14	Patient-centred management of Parkinson's disease. <i>Lancet Neurology</i> , 2020 , 19, 887-888	24.1	0
13	Thyrotoxicosis Resulting in Unilateral Upper Limb Chorea and Ballismus. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 1-2	1	0
12	The Disease Modification Conundrum in Parkinson's Disease: Failures and Hopes.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 810860	5.3	0
11	Coping Styles in Patients with Parkinson's Disease: Consideration in the Co-Designing of Integrated Care Concepts. <i>Journal of Personalized Medicine</i> , 2022 , 12, 921	3.6	0
10	Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations". <i>Movement Disorders</i> , 2017 , 32, 482	7	
9	Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 245-246	3.6	
8	Emerging targets and other stimulation-related procedures in the management of Parkinson's disease216-230		
7	A12 How does Enroll-HD expedite/facilitate the conduct of clinical trials?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, A4.1-A4	5.5	
6	I31 Enroll-HD: current status. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, A69.2-A70	5.5	

- 5 I30 Enroll-HD: a global clinical research platform for huntington's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A69.1-A69 5.5
- 4 Intermittent undulating tongue as an involuntary movement in early amyotrophic lateral sclerosis. *Parkinsonism and Related Disorders*, **2019**, 67, 1-2 3.6
- 3 PO104 Placebo and nocebo responses in rls: a meta-analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, A39.1-A39 5.5
- 2 Assessing and managing Parkinson's disease from home: A 21st century vision closer to reality. *Movement Disorders*, **2018**, 33, 1407 7
- 1 Return on Investment Analysis for the Integrated Parkinson's Care Network: Lesson Learned from a Pilot Study. *Journal of Parkinsons Disease*, **2021**, 11, 2085-2091 5.3